Telix Pharmaceuticals Limited share price logo

Telix Pharmaceuticals Limited

NASDAQ: TLX

Mid Cap

$10.39

-0.44

(-4.06%)

as on

Telix Pharmaceuticals Limited Stock Performance

as on May 13, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $10.26
    $10.63
    downward going graph

    1.25%

    Downside

    2.31%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $6.28
    $18.49
    downward going graph

    39.56%

    Downside

    77.96%

    Upside

    downward going graph

Telix Pharmaceuticals Limited share price movements today

Previous Close
$10.83
Open
$10.58
Volume
209.9K
Day's Low - High
$10.26 - $10.63
52 Week Low - High
$6.28 - $18.49

Telix Pharmaceuticals Limited Historical Returns

1 Month Return
-7.56 %
3 Month Return
+ 58.87 %
1 Year Return
-37.82 %
3 Year Return
0 %
5 Year Return
0 %

Telix Pharmaceuticals Limited Stock Fundamentals & Key Indicators

Check Telix Pharmaceuticals Limited market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.7B

EPS (TTM)

0.1049

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-1.86%

Telix Pharmaceuticals Limited vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Telix Pharmaceuticals Limited with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Telix Pharmaceuticals Limited image
Telix Pharmaceuticals Limited
NA$3.7BNANA-0.89%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$38.0B119.7%71.3912.55%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.7BNA71.448.94%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.4B109.14%25.8435.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.7B39.88%17.3929.65%

Stock Returns calculator for Telix Pharmaceuticals Limited Stock including INR - Dollar returns

The Telix Pharmaceuticals Limited stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Telix Pharmaceuticals Limited investment value today

Current value as on today

₹69,784

Returns

-₹30,216

(-30.22%)

Returns from Telix Pharmaceuticals Limited Stock

-₹37,822 (-37.82%)

Dollar Impact

₹7,605 (+7.61%)

Indian Investors' Interest in Telix Pharmaceuticals Limited Stock

Search interest for Telix Pharmaceuticals Limited Stock has increased by 22% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:22% versus previous 30 day period

Telix Pharmaceuticals Limited Quarterly Profit & Loss

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Total Revenue
2
4
24
136
220
281
188
594
593
620
Gross Profit
-11
-18
-15
44
90
223
123
385
288
327
Operating Income
-31
-49
-63
-9
31
20
13
68
15
9
EBITDA
-33
-59
-67
-24
-8
22
40
76
8
28
Interest Expense
0
0
0
0
0
0
4
16
3
11
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-37
-61
-70
-27
-12
15
9
46
-7
0
Income Tax Expense
-4
-13
0
5
2
-4
-2
8
3
6
Net Income
-32
-47
-70
-33
-14
19
11
38
-3
-7
Net Profit Margin
-1117.32%
-1024.24%
-294.80%
-24.39%
-6.48%
6.93%
6.18%
6.43%
-0.59%
-1.17%

Telix Pharmaceuticals Limited Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
29
31
0
3
5
7
160
336
495
1,205
Gross Profit
8
0
0
-11
-16
-29
29
210
322
640
Operating Income
0
-6
-15
-40
-49
-81
-91
51
82
26
EBITDA
0
-6
-25
-24
-44
-70
-92
22
98
79
Interest Expense
0
0
0
2
1
0
0
13
21
55
Depreciation
-
-
-
-
4
5
5
6
-
-
Income Before Tax
0
-6
-15
-42
-60
-99
-98
3
56
-7
Income Tax Expense
0
0
-1
-14
-15
-18
5
-2
6
2
Net Income
0
-6
-13
-27
-44
-80
-104
3
31
-10
Net Profit Margin
-0.15%
-20.07%
-7087.06%
-799.63%
-861.06%
-1059.90%
-65.01%
1.04%
6.37%
-0.89%

Telix Pharmaceuticals Limited Quarterly Cash Flow

All numbers in Millions USD

Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Net Income
-47
-70
-33
-14
19
29
20
-3
-7
Operating Cash Flow
-30
-60
-3
13
10
34
3
26
-52
Investing Cash Flow
-1
-11
-5
-2
-22
-45
-89
-396
-41
Financing Cash Flow
2
171
3
4
5
2
636
-4
-1
Change in Cash
-27
100
-6
15
-8
-7
591
-356
-97

Telix Pharmaceuticals Limited Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-6
-13
-27
-44
-80
-104
5
49
-10
Operating Cash Flow
-6
-20
-23
1
-59
-63
23
43
-25
Investing Cash Flow
0
-2
0
-1
-2
-16
-25
-135
-428
Financing Cash Flow
54
0
42
34
2
174
10
638
-5
Change in Cash
54
-22
18
33
-55
94
6
587
-446

Telix Pharmaceuticals Limited News & Key Events

  • img

    Today's Timeline - 13 April

    Mon, 04:18 PM

    -

    Telix partners with Regeneron for up to $4.3 billion in radiopharmaceutical therapies, receiving $40 million upfront.

    Mon, 06:08 PM

    -

    Telix's FDA accepted NDA for TLX101-Px1; shares rose 5.79% in premarket trading.

Insights on Telix Pharmaceuticals Limited

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, TLX stock has moved up by 58.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, BeOne Medicines Ltd has given 40.2% return, outperforming this stock by 78.0%

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
OrganisationTelix Pharmaceuticals Limited
Headquarters55 Flemington Road, North Melbourne, VIC, Australia, 3051
IndustryBiotechnology
CEODr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
E-voting on sharesClick here to vote

Key Management of Telix Pharmaceuticals Limited

Name

Title

Thomas Fromm

Vice President of Sales

Ms. Meredith Crowe BDES

Senior Vice President of Global People & Culture

Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D

Co-Founder, MD, Group CEO & Executive Director

Mr. Darren Smith B.Bus., FCPA, M.B.A.

Group Chief Financial Officer

Mr. Darren Patti Pharm.D.

Group Chief Operating Officer

Dr. David N. Cade M.B.A., M.D., MBBS

Group Chief Medical Officer

Dr. Paul Schaffer

SVP of Research & Development

Mr. Craig Ulrick

Chief Information Officer

Ms. Kyahn Williamson B.A.

Senior Vice President of Corporate Communications & Investor Relations

Mr. Christian Krautkramer J.D.

Group General Counsel

FAQs

What is Telix Pharmaceuticals Limited share price today?

Telix Pharmaceuticals Limited share price today is $10.39 as on at the close of the market. Telix Pharmaceuticals Limited share today touched a day high of $10.63 and a low of $10.26.

What is the 52 week high and 52 week low for Telix Pharmaceuticals Limited share?

Telix Pharmaceuticals Limited share touched a 52 week high of $18.49 on and a 52 week low of $6.28 on . Telix Pharmaceuticals Limited stock price today i.e. is closed at $10.39,which is 43.81% down from its 52 week high and 65.45% up from its 52 week low.

What is Telix Pharmaceuticals Limited's market capitalisation today?

Telix Pharmaceuticals Limited market capitalisation is $0.00T as on .

How to invest in Telix Pharmaceuticals Limited Stock (TLX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Telix Pharmaceuticals Limited on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Telix Pharmaceuticals Limited Shares that will get you 0.1444 shares as per Telix Pharmaceuticals Limited share price of $10.39 per share as on May 13, 2026 at 8:45 am IST.

What is the minimum amount required to buy Telix Pharmaceuticals Limited Stock (TLX) from India?

Indian investors can start investing in Telix Pharmaceuticals Limited (TLX) shares with as little as ₹95.705 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in Telix Pharmaceuticals Limited stock (as per the Rupee-Dollar exchange rate as on ). Based on Telix Pharmaceuticals Limited share’s latest price of $10.39 as on May 13, 2026 at 8:45 am IST, you will get 0.9625 shares of Telix Pharmaceuticals Limited. Learn more about fractional shares .